Does the media favor OBIO or AVR?

In the previous week, Orchestra BioMed and Orchestra BioMed both had 5 articles in the media. Anteris Technologies Global's average media sentiment score of 1.21 beat Orchestra BioMed's score of 0.16 indicating that Anteris Technologies Global is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anteris Technologies Global 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DRTS or OBIO?

In the previous week, Alpha Tau Medical had 4 more articles in the media than Orchestra BioMed. MarketBeat recorded 9 mentions for Alpha Tau Medical and 5 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 0.16 beat Alpha Tau Medical's score of -0.26 indicating that Orchestra BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Tau Medical 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, OBIO or INMD?

InMode has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orchestra BioMed $33.48M 6.98 -$52.70M -$0.97 N/A InMode $370.49M 2.32 $93.83M $1.36 9.96

Is OBIO or INMD more profitable?

InMode has a net margin of 23.27% compared to Orchestra BioMed's net margin of -166.96%. InMode's return on equity of 13.47% beat Orchestra BioMed's return on equity. Company Net Margins Return on Equity Return on Assets Orchestra BioMed -166.96% -157.46% -60.18% InMode 23.27% 13.47% 11.95%

Does the media prefer OBIO or INMD?

In the previous week, Orchestra BioMed had 3 more articles in the media than InMode. MarketBeat recorded 5 mentions for Orchestra BioMed and 2 mentions for InMode. Orchestra BioMed's average media sentiment score of 0.16 beat InMode's score of 0.00 indicating that Orchestra BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InMode 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to OBIO or SSII?

In the previous week, Orchestra BioMed had 4 more articles in the media than SS Innovations International. MarketBeat recorded 5 mentions for Orchestra BioMed and 1 mentions for SS Innovations International. Orchestra BioMed's average media sentiment score of 0.16 beat SS Innovations International's score of 0.00 indicating that Orchestra BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SS Innovations International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CBLL or OBIO more profitable?

CeriBell has a net margin of -63.51% compared to Orchestra BioMed's net margin of -166.96%. CeriBell's return on equity of -38.19% beat Orchestra BioMed's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -63.51% -38.19% -30.92% Orchestra BioMed -166.96% -157.46% -60.18%

Does the media prefer CBLL or OBIO?

In the previous week, Orchestra BioMed had 4 more articles in the media than CeriBell. MarketBeat recorded 5 mentions for Orchestra BioMed and 1 mentions for CeriBell. Orchestra BioMed's average media sentiment score of 0.16 beat CeriBell's score of 0.00 indicating that Orchestra BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Orchestra BioMed (OBIO) Competitors

$3.90 -0.09 (-2.26%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$3.89 -0.01 (-0.26%)

As of 06/5/2026 04:10 PM Eastern

Compare

OBIO vs. AVR, DRTS, INMD, SSII, and CBLL

Should you buy Orchestra BioMed stock or one of its competitors? MarketBeat compares Orchestra BioMed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Orchestra BioMed include Anteris Technologies Global (AVR), Alpha Tau Medical (DRTS), InMode (INMD), SS Innovations International (SSII), and CeriBell (CBLL). These companies are all part of the "medical equipment" industry.

How does Orchestra BioMed compare to Anteris Technologies Global?

Orchestra BioMed (NASDAQ:OBIO) and Anteris Technologies Global (NASDAQ:AVR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Orchestra BioMed has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	6.98	-$52.70M	-$0.97	N/A
Anteris Technologies Global	$1.91M	491.29	-$94.14M	-$2.23	N/A

Orchestra BioMed has a net margin of -166.96% compared to Anteris Technologies Global's net margin of -5,148.78%. Anteris Technologies Global's return on equity of -124.76% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
Anteris Technologies Global	-5,148.78%	-124.76%	-101.21%

53.2% of Orchestra BioMed shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by company insiders. Comparatively, 4.5% of Anteris Technologies Global shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Orchestra BioMed and Orchestra BioMed both had 5 articles in the media. Anteris Technologies Global's average media sentiment score of 1.21 beat Orchestra BioMed's score of 0.16 indicating that Anteris Technologies Global is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anteris Technologies Global	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Orchestra BioMed has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Anteris Technologies Global has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market.

Orchestra BioMed presently has a consensus price target of $13.60, suggesting a potential upside of 248.72%. Anteris Technologies Global has a consensus price target of $16.00, suggesting a potential upside of 65.98%. Given Orchestra BioMed's higher possible upside, equities analysts clearly believe Orchestra BioMed is more favorable than Anteris Technologies Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Orchestra BioMed beats Anteris Technologies Global on 10 of the 15 factors compared between the two stocks.

How does Orchestra BioMed compare to Alpha Tau Medical?

Alpha Tau Medical (NASDAQ:DRTS) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

2.7% of Alpha Tau Medical shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 39.5% of Alpha Tau Medical shares are held by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Alpha Tau Medical has a net margin of 0.00% compared to Orchestra BioMed's net margin of -166.96%. Alpha Tau Medical's return on equity of -73.23% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-73.23%	-52.90%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

In the previous week, Alpha Tau Medical had 4 more articles in the media than Orchestra BioMed. MarketBeat recorded 9 mentions for Alpha Tau Medical and 5 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 0.16 beat Alpha Tau Medical's score of -0.26 indicating that Orchestra BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Tau Medical	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Tau Medical has higher earnings, but lower revenue than Orchestra BioMed. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.67	N/A
Orchestra BioMed	$33.48M	6.98	-$52.70M	-$0.97	N/A

Alpha Tau Medical presently has a consensus price target of $12.60, indicating a potential upside of 34.76%. Orchestra BioMed has a consensus price target of $13.60, indicating a potential upside of 248.72%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Alpha Tau Medical has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Summary

Alpha Tau Medical beats Orchestra BioMed on 8 of the 15 factors compared between the two stocks.

How does Orchestra BioMed compare to InMode?

Orchestra BioMed (NASDAQ:OBIO) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

In the previous week, Orchestra BioMed had 3 more articles in the media than InMode. MarketBeat recorded 5 mentions for Orchestra BioMed and 2 mentions for InMode. Orchestra BioMed's average media sentiment score of 0.16 beat InMode's score of 0.00 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InMode	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by company insiders. Comparatively, 6.9% of InMode shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

InMode has a net margin of 23.27% compared to Orchestra BioMed's net margin of -166.96%. InMode's return on equity of 13.47% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
InMode	23.27%	13.47%	11.95%

InMode has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	6.98	-$52.70M	-$0.97	N/A
InMode	$370.49M	2.32	$93.83M	$1.36	9.96

Orchestra BioMed currently has a consensus target price of $13.60, suggesting a potential upside of 248.72%. InMode has a consensus target price of $16.00, suggesting a potential upside of 18.17%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, equities research analysts plainly believe Orchestra BioMed is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Orchestra BioMed has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, InMode has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market.

Summary

InMode beats Orchestra BioMed on 9 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to SS Innovations International?

Orchestra BioMed (NASDAQ:OBIO) and SS Innovations International (NASDAQ:SSII) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

SS Innovations International has higher revenue and earnings than Orchestra BioMed. SS Innovations International is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	6.98	-$52.70M	-$0.97	N/A
SS Innovations International	$42.49M	17.80	-$12.13M	-$0.05	N/A

SS Innovations International has a net margin of -20.69% compared to Orchestra BioMed's net margin of -166.96%. SS Innovations International's return on equity of -23.00% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
SS Innovations International	-20.69%	-23.00%	-13.18%

Orchestra BioMed currently has a consensus price target of $13.60, suggesting a potential upside of 248.72%. SS Innovations International has a consensus price target of $7.00, suggesting a potential upside of 85.19%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, equities analysts plainly believe Orchestra BioMed is more favorable than SS Innovations International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

53.2% of Orchestra BioMed shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Orchestra BioMed has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, SS Innovations International has a beta of -1.88, suggesting that its stock price is 288% less volatile than the broader market.

In the previous week, Orchestra BioMed had 4 more articles in the media than SS Innovations International. MarketBeat recorded 5 mentions for Orchestra BioMed and 1 mentions for SS Innovations International. Orchestra BioMed's average media sentiment score of 0.16 beat SS Innovations International's score of 0.00 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SS Innovations International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Orchestra BioMed beats SS Innovations International on 9 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to CeriBell?

CeriBell (NASDAQ:CBLL) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Orchestra BioMed has lower revenue, but higher earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.77	-$53.41M	-$1.63	N/A
Orchestra BioMed	$33.48M	6.98	-$52.70M	-$0.97	N/A

CeriBell has a net margin of -63.51% compared to Orchestra BioMed's net margin of -166.96%. CeriBell's return on equity of -38.19% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

53.2% of Orchestra BioMed shares are owned by institutional investors. 20.1% of CeriBell shares are owned by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CeriBell has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

In the previous week, Orchestra BioMed had 4 more articles in the media than CeriBell. MarketBeat recorded 5 mentions for Orchestra BioMed and 1 mentions for CeriBell. Orchestra BioMed's average media sentiment score of 0.16 beat CeriBell's score of 0.00 indicating that Orchestra BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CeriBell currently has a consensus target price of $22.20, indicating a potential upside of 21.64%. Orchestra BioMed has a consensus target price of $13.60, indicating a potential upside of 248.72%. Given Orchestra BioMed's higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

CeriBell beats Orchestra BioMed on 9 of the 17 factors compared between the two stocks.

Get Orchestra BioMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBIO vs. The Competition

Export

Metric	Orchestra BioMed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$238.92M	$3.36B	$6.47B	$12.46B
Dividend Yield	N/A	2.31%	2.67%	5.34%
P/E Ratio	-4.02	18.38	23.69	23.63
Price / Sales	6.98	299.54	520.34	114.17
Price / Cash	N/A	114.83	42.35	57.17
Price / Book	4.11	6.51	9.73	6.37
Net Income	-$52.70M	$24.09M	$3.56B	$337.36M
7 Day Performance	-0.26%	-6.95%	-2.92%	-2.38%
1 Month Performance	-5.11%	-4.20%	-0.85%	-0.57%
1 Year Performance	17.82%	36.83%	22.23%	25.53%

Orchestra BioMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBIO Orchestra BioMed	4.5991 of 5 stars	$3.90 -2.3%	$13.60 +248.7%	+27.9%	$238.92M	$33.48M	N/A	4	Positive News
AVR Anteris Technologies Global	4.0038 of 5 stars	$9.29 +2.1%	$16.00 +72.2%	+94.4%	$885.81M	$1.91M	N/A	138	Insider Trade Options Volume
DRTS Alpha Tau Medical	3.2396 of 5 stars	$8.93 -7.6%	$12.20 +36.6%	+220.8%	$873.00M	N/A	N/A	80	Analyst Forecast Insider Trade Options Volume
INMD InMode	2.2291 of 5 stars	$13.50 -0.7%	$16.00 +18.5%	-5.6%	$861.05M	$374.64M	9.93	480	Positive News
SSII SS Innovations International	1.8742 of 5 stars	$4.01 +1.8%	N/A	-37.0%	$788.52M	$42.49M	N/A	4	Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OBIO) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Orchestra BioMed (OBIO) Competitors

OBIO vs. AVR, DRTS, INMD, SSII, and CBLL

How does Orchestra BioMed compare to Anteris Technologies Global?

Summary

How does Orchestra BioMed compare to Alpha Tau Medical?

Summary

How does Orchestra BioMed compare to InMode?

Summary

How does Orchestra BioMed compare to SS Innovations International?

Summary

How does Orchestra BioMed compare to CeriBell?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO vs. The Competition

Orchestra BioMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Orchestra BioMed (OBIO) Competitors

OBIO vs. AVR, DRTS, INMD, SSII, and CBLL

How does Orchestra BioMed compare to Anteris Technologies Global?

Which has better valuation & earnings, OBIO or AVR?

Is OBIO or AVR more profitable?

Do insiders and institutionals have more ownership in OBIO or AVR?

Does the media favor OBIO or AVR?

Which has more volatility and risk, OBIO or AVR?

Do analysts recommend OBIO or AVR?

Summary

How does Orchestra BioMed compare to Alpha Tau Medical?

Do institutionals & insiders have more ownership in DRTS or OBIO?

Is DRTS or OBIO more profitable?

Does the media favor DRTS or OBIO?

Which has stronger earnings & valuation, DRTS or OBIO?

Do analysts prefer DRTS or OBIO?

Which has more volatility and risk, DRTS or OBIO?

Summary

How does Orchestra BioMed compare to InMode?

Does the media prefer OBIO or INMD?

Do insiders & institutionals hold more shares of OBIO or INMD?

Is OBIO or INMD more profitable?

Which has stronger earnings & valuation, OBIO or INMD?

Do analysts rate OBIO or INMD?

Which has more volatility and risk, OBIO or INMD?

Summary

How does Orchestra BioMed compare to SS Innovations International?

Which has stronger valuation and earnings, OBIO or SSII?

Is OBIO or SSII more profitable?

Do analysts prefer OBIO or SSII?

Do insiders and institutionals believe in OBIO or SSII?

Which has more volatility and risk, OBIO or SSII?

Does the media refer more to OBIO or SSII?

Summary

How does Orchestra BioMed compare to CeriBell?

Which has preferable earnings and valuation, CBLL or OBIO?

Is CBLL or OBIO more profitable?

Do institutionals and insiders have more ownership in CBLL or OBIO?

Which has more risk and volatility, CBLL or OBIO?

Does the media prefer CBLL or OBIO?

Do analysts prefer CBLL or OBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO vs. The Competition

Orchestra BioMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools